Predictive and Prognostic Biomarkers for Response to Neoadjuvant Chemotherapy for Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 380
Special Issue Editor
Interests: neoadjuvant chemotherapy; breast cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Breast cancer (BC) is the most commonly occurring cancer in women, with 2.26 million new BC cases being diagnosed each year. Recently, BC has come to be considered as a heterogeneous group of tumours with regard to clinical presentation, epidemiology, histology, radiology, gene expression, prognosis, and response to treatment. Subsequently, the management of BC continues to present a significant clinical challenge, considering that these tumours often do not respond to targeted therapeutic agents and are more diverse than we originally thought.
Preoperative neoadjuvant cytotoxic chemotherapy (NACT) is a standard treatment option for triple-negative and HER2+ BC subtypes, in addition to HER2-targeting agents, as it downsizes tumours prior to loco-regional treatment with surgery and radiotherapy, provides an in vivo chemo-sensitivity test for the patient, and enables the deployment of more intensive adjuvant chemotherapy and the consideration of novel adjuvant treatment for chemo-resistant tumours. Monitoring tumour size reduction after each treatment cycle allows doctors to switch to a different chemotherapy regimen if standard drugs show no response or to fast-track the patient to undergoing immediate surgery. However, this relies on accurate clinical examination. With the current patient selection criteria and cycle-based response monitoring for NACT, only 30-50% of BC patients achieve a pCR (microscopic absence of tumour at surgery), which is generally associated with an excellent prognosis. Meanwhile, the remaining 50-70% patients with no pCR (residual disease) show a wide range of responses to NACT, from near-pCR to complete resistance, and diverse clinical outcomes (e.g., in terms of survival rates); posing a challenge in BC planning and management. Moreover, there is no reliable and efficient clinical pipeline to accurately stratify patients before, during, and after NACT according to the likelihood of treatment response and effectiveness.
Therefore, there is an urgent need to identify new prognostic and predictive features that could accurately sub-stratify BC, monitor and grade responses to chemotherapy, and tailor and guide treatment for individual patients to avoid serious toxicity and the economic burden on health systems caused by unnecessary ineffective therapies.
For this Special Issue, submissions of original research articles and reviews are welcome.
I look forward to receiving your contributions.
Dr. Tarek M. A. Abdel-Fatah
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- predictive and prognostic biomarkers
- neoadjuvant chemotherapy
- HER2-targeting agents
- complete pathological response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
